Fig. 2

CCR5 antagonist TAK-779 protects CD4 T cell from R3A-induced bystander CD4 T cell depletion a PBMCs were treated with CCR5 antagonist TAK-779 (5 μM) before infection with R3A and maintained after infection. HIV-1 viral replication in CD4 T cells was measured by intracellular p24 staining or by extracellular HIV-1 reverse transcriptase levels. b CD4 T cell depletion by R3A in the presence of TAK-779 was measured by FACS analysis as described in Fig. 1b. %CD4 T cells over time relative to mock infected PBCMCs are presented. c Cell viability of bystander and infected CD4 T cells during R3A infection in the presence of TAK-779 was analyzed as described in Fig. 1c. d Graphical summary of viral induced bystander cell death from c, presented as cell death percentage of p24(−) CD4 T cells at 6 days post infection. Experimental results were repeated with PBMCs from 2 different blood donors. *p < 0.05